Skip to main content
. 2013 Jun 25;109(2):502–511. doi: 10.1038/bjc.2013.320

Figure 5.

Figure 5

Relationship between SMARCC1 expression and survival after recurrence. Survival after recurrence curves showed a significantly better survival rate for SMARCC1-positive patients than for SMARCC1-negative patients treated with gemcitabine therapy (*P=0.0463), but survival was not significantly different in patients treated without gemcitabine therapy (P=0.9095).